| Literature DB >> 30329218 |
Kentaro Miura1, Kazutoshi Hamanaka1, Shunichiro Matsuoka1, Tetsu Takeda1, Hiroyuki Agatsuma1, Akira Hyogotani1, Ken-Ichi Ito1, Fumihiro Nishimaki2, Tomonobu Koizumi3, Takeshi Uehara4.
Abstract
BACKGROUND: Liposarcoma has been subclassified histologically into well-differentiated, myxoid, pleomorphic, and dedifferentiated types. The dedifferentiated type generally shows poorer prognosis than the well-differentiated type. Because of its rarity, the clinicopathological features and clinical outcomes of primary mediastinal dedifferentiated liposarcoma remain unclear.Entities:
Keywords: Dedifferentiated liposarcoma; local recurrence; mediastinum
Mesh:
Substances:
Year: 2018 PMID: 30329218 PMCID: PMC6275824 DOI: 10.1111/1759-7714.12888
Source DB: PubMed Journal: Thorac Cancer ISSN: 1759-7706 Impact factor: 3.500
Figure 1Chest computed tomography scans in Case 1 (a) preoperatively and (b) at recurrence. A 121 × 82 × 58 mm tumor was observed extending from the cervical region to the middle mediastinum with homogenous low density. Solitary local recurrence was observed in the middle mediastinum 51 months after surgery.
Figure 2Chest computed tomography scans in Case 2 (a) preoperatively and (b) at recurrence. A 66 × 88 mm tumor was observed in the middle mediastinum with homogenous density. Tumor recurrence was detected in the posterior mediastinum after 28 months.
Figure 3Chest computed tomography (CT) scans in Case 3 (a) preoperatively and (b) at recurrence. A 66 × 30 mm tumor was observed in the anterior mediastinum, which had heterogeneous areas of low and high density. After 28 months, follow‐up chest CT showed recurrent tumors behind the sternum.
Figure 4Histopathological findings in Case 3. Hematoxylin and eosin staining revealed spindle tumor cells proliferate with fibrous stroma. Immunohistochemical analysis was positive for CDK4 and slightly positive for MDM2.
Figure 5Preoperative computed tomography scan in Case 4. A huge tumor was detected in the posterior mediastinum, which projected on either side of the intrathoracic space. The esophagus was surrounded by the tumor.
Figure 6Chest computed tomography scan of Case 5 at the first visit. A giant tumor was observed in the middle and posterior mediastinum extensively surrounding the trachea.
Summary of our five cases
| Case | Age | Gender | Location | Symptom | Tumor size (cm) | SUVmax | Ki‐67 (%) | FNCLCC grade | Initial treatment | Surgical approach | Recurrence | RFS (months) | Treatment for recurrence | OS | OS status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 45 | F | Middle | None | 12.7 | 1.9 | < 10 | 2 | Surgery | Cervical approach, right sided VATS | Yes | 51 | Surgery | 60 | Alive |
| 2 | 62 | F | Superior | None | 12 | 2.5 | 20 | 2 | Surgery | Sternotomy | Yes | 28 | RT | 48 | Alive |
| 3 | 84 | M | Anterior | None | 6.6 | 9.2 | 50 | 2 | Surgery | Sternotomy | Yes | 27 | Surgery | 40 | Alive |
| 4 | 75 | M | Posterior | None | 20 | 2.0 | 3 | 2 | Surgery | Bilateral thoracotomy | No | 3 | — | 3 | Alive |
| 5 | 78 | M | Middle | Dyspnea, Hoarseness | 11 | 5.1 | 40 | 2 | Chemo (Doxorubicin) | — | — | — | — | 0.5 | Dead |
Chemo, chemotherapy; FNCLCC, French Federation Nationale des Centres de Lutte Contre le Cancer; OS, overall survival; FRS, recurrence‐free survival; RT, radiotherapy; SUVmax, maximum standardized uptake value; VATS, video‐assisted thoracoscopic surgery.
Literature review of 19 cases published between 2002 and 2016, including our five cases
| Authors | No. ofpatients | Age | Gender | Location | Symptom | Tumor size (cm) | Initial treatment | Surgical approach | Recurrence | RFS (months) | Treatment for recurrence | OS | OS status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boland | 5 | 68 | M | Posterior | Unknown | Unknown | Surgery | Unknown | Yes | 48 | Unknown | 72 | Alive |
| 63 | F | Anterior | Unknown | Unknown | Surgery | Unknown | Yes | 24 | Unknown | 34 | Dead | ||
| 47 | F | Middle | Unknown | Unknown | Surgery | Unknown | No | 60 | Unknown | 60 | Alive | ||
| 71 | F | Posterior | Unknown | Unknown | Surgery (incomplete) | Unknown | Residual | 12 | Unknown | 12 | Alive | ||
| 76 | F | Anterior | Unknown | Unknown | Unknown | Unknown | Unknown | Unknown | Unknown | Unknown | Unknown | ||
| Ortega | 3 | 75 | M | Posterior | Weight loss, dyspnea | 14 | Surgery | Unknown | Yes | Unknown | Unknown | 6 | Alive |
| 66 | M | Posterior | Chest pain, dysphagia, malaise | 9 | Surgery | Unknown | No | Unknown | — | 24 | Alive | ||
| 53 | F | Posterior | Dysphagia | 23 | Surgery | Unknown | Unknown | Unknown | Unknown | Unknown | Unknown | ||
| Chen | 1 | 64 | M | Unknown | Unknown | 6 | Surgery | Unknown | No | 12 | — | 12 | Alive |
| Fukai | 1 | 56 | M | Anterior | None | 16.5 | Surgery | Sternotomy | No | 36 | — | 36 | Alive |
| Hamanaka | 1 | 74 | M | Posterior | Dry cough | 11 | Surgery | Lateral thoracotomy | No | 8 | — | 8 | Alive |
| Coulibaly | 1 | 34 | F | Posterior | Dyspnoea | 20 | Surgery | Lateral thoracotomy | Yes | 15 | Surgery (incomplete) | 114 | Dead |
| Narasimman | 1 | 48 | M | Posterior | None | 15 | Surgery | Lateral thoracotomy | No | 12 | — | 12 | Alive |
| Hirai | 1 | 64 | M | Anterior | Hoarseness | 6.5 | Surgery | Sternotomy | No | 14 | — | 14 | Alive |
| Miura | 5 | 45 | F | Middle | None | 12.7 | Surgery | Cervical approach, right sided VATS | Yes | 51 | Surgery | 60 | Alive |
| 62 | F | Superior | None | 12 | Surgery | Sternotomy | Yes | 28 | RT | 48 | Alive | ||
| 84 | M | Anterior | None | 6.6 | Surgery | Sternotomy | Yes | 27 | Surgery | 40 | Alive | ||
| 75 | M | Posterior | None | 20 | Surgery | Bilateral thoracotomy | No | 3 | — | 3 | Alive | ||
| 78 | M | Superior | Dyspnea, Hoarseness | 11 | Chemo (Doxorubicin) | — | — | — | — | 0.5 | Dead |
Chemo, chemotherapy; OS, overall survival; FRS, recurrence‐free survival; RT, radiotherapy; SUVmax, maximum standardized uptake value; VATS, video‐assisted thoracoscopic surgery.